Tonsillectomy plus immunosuppression boosts early remission in white IgA nephropathy patients
A nonrandomized study of 221 white patients with high-risk IgA nephropathy links adding tonsillectomy to immunosuppression with more remission and less kidney decline.
Summary
IgA nephropathy is a chronic autoimmune kidney disease. Immune activation in mucosal tissue, including the tonsils, produces abnormal IgA1 that forms immune complexes and lodges in the kidney's filters, causing progressive damage. Tonsillectomy plus steroids is standard in Japan, but guidelines discourage surgery in non-Asian patients because evidence is lacking. A single-center, nonrandomized study from Russia followed 221 white patients at high risk of progression for a median of 33 months. Of these, 85 had tonsillectomy plus immunosuppression and 136 had immunosuppression alone. Early overall remission was 95.2% versus 72.6%, and complete remission was 33.9% versus 11.3%. Kidney function decline or kidney failure occurred in 3.5% versus 28.9%. Results held after propensity-score matching. Because patients were not randomized, unmeasured differences may explain some of the gap, so this is a signal worth testing in a randomized trial, not a reason to change practice yet.
Detailed Summary
IgA nephropathy (IgAN) is a chronic autoimmune kidney disease and a major cause of kidney failure in younger and middle-aged adults. Kidney function is a core healthspan issue, and this disease shows how immune dysregulation at mucosal surfaces can slowly wear down an organ.
The proposed mechanism is straightforward. Mucosa-associated lymphoid tissue, including the tonsils, produces galactose-deficient IgA1. This forms immune complexes that deposit in the glomeruli and trigger inflammation and scarring. Removing a source of the trigger while suppressing glomerular inflammation is biologically plausible. Tonsillectomy with pulsed steroids is established in Japan, but international guidelines steer away from surgery in non-Japanese patients because of limited evidence.
The new study, published in Nephrology Dialysis Transplantation, was a single-center, nonrandomized, prospective comparison of 221 white patients with high-risk primary IgAN. Eighty-five had tonsillectomy plus immunosuppression and 136 had immunosuppression alone. Nearly all took renin-angiotensin inhibitors, and most received steroid monotherapy. Median follow-up was 33 months. Early overall remission was 95.2% versus 72.6% (HR 3.36), and early complete remission was 33.9% versus 11.3% (HR 6.32). Progression, defined as a 40% eGFR drop, eGFR below 15, or kidney replacement therapy, occurred in 3.5% versus 28.9% (adjusted HR 0.13). Results were consistent after 1:1 propensity-score matching.
The author argued that these remission rates exceed the 30% to 62% proteinuria reductions seen with targeted-release budesonide, complement inhibitors, and anti-BAFF/APRIL agents. That comparison is across different studies, so it is not direct.
The main caveat is design. Without randomization, unmeasured confounding and selection bias remain possible, even after matching. The study is single-center and follow-up is moderate, and the excerpt does not report surgical complications. Patients with high-risk IgAN may reasonably ask a nephrologist about this evidence, but randomized trials in non-Asian populations are needed.
Key Findings
- Design: single-center, nonrandomized, prospective study of 221 white patients with high-risk IgAN; 85 had tonsillectomy plus immunosuppression, 136 immunosuppression alone.
- Early overall remission was 95.2% with surgery versus 72.6% without (HR 3.36); complete remission was 33.9% versus 11.3% (HR 6.32).
- Kidney function decline or failure occurred in 3.5% with tonsillectomy versus 28.9% (adjusted HR 0.13), over a median 33 months.
- Results held after 1:1 propensity-score matching, but nonrandomized design cannot rule out unmeasured confounding.
- Guidelines currently discourage tonsillectomy outside Asian cohorts; this study is hypothesis-strengthening, not practice-changing.
Methodology
This is a news report in MedPage Today on a prospective, nonrandomized, single-center comparative study in Nephrology Dialysis Transplantation, with quotes from the author. Evidence is observational-comparative in humans, with clinical endpoints (remission, eGFR decline, kidney replacement) and propensity-score matching. The excerpt was truncated, so full details such as complications and subgroup data were not available.
Study Limitations
Nonrandomized, single-center design leaves room for selection bias and unmeasured confounding despite matching. Follow-up is a median of 33 months, short for a slowly progressive disease, and comparisons with budesonide, complement inhibitor, and anti-BAFF/APRIL trials are indirect. Check the primary paper for surgical complication rates, baseline group differences, and long-term outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
